Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Everolimus
100%
Tuberous Sclerosis Complex
100%
Real-world Clinical Practice
100%
Adverse Effects
57%
Renal Angiomyolipoma
57%
Clinical Practice
42%
Subependymal Giant Cell Astrocytoma
42%
Treatment Duration
28%
Seizure Reduction
28%
Antiseizure Medication
28%
Denmark
14%
Placebo-controlled
14%
Life-limiting Conditions
14%
Anemia
14%
Norway
14%
Cholesterol
14%
Seizure Frequency
14%
Epilepsy
14%
Inpatient Treatment
14%
Young Age
14%
Nineteen
14%
Upper Respiratory Tract Infection
14%
Patients with Epilepsy
14%
Laboratory Abnormalities
14%
Stomatitis
14%
Close Follow-up
14%
Oral Ulcer
14%
Longest Diameter
14%
Medicine and Dentistry
Everolimus
100%
Tuberous Sclerosis
100%
Epileptic Seizure
71%
Angiomyolipoma
57%
Adverse Effect
57%
Subependymal Giant Cell Astrocytoma
42%
Treatment Duration
28%
Placebo
14%
Anemia
14%
Upper Respiratory Tract Infection
14%
Epilepsy
14%
Patient with Epilepsy
14%
Mouth Ulcer
14%
Cholesterol
14%
Stomatitis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Everolimus
100%
Tuberous Sclerosis
100%
Angiomyolipoma
57%
Adverse Effect
57%
Subependymal Giant Cell Astrocytoma
42%
Epilepsy
28%
Placebo
14%
Upper Respiratory Tract Infection
14%
Anemia
14%
Mouth Ulcer
14%
Cholesterol
14%
Stomatitis
14%